Kanaph Therapeutics Funding: $73M Raised, Series C (2024)
Kanaph Therapeutics is based in Seoul, South Korea. It has raised $73M in total funding. Latest round: Series C.
Kanaph Therapeutics funding overview
Kanaph Therapeutics is based in Seoul, South Korea. Kanaph Therapeutics has raised $73M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series C announced in January 2024. The round record for Kanaph Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Lotte Biologics, GC Pharma, InterVest, Premier Partners, Solidus Investment, Daily Partners and 3 others. 9 distinct backers are named across the disclosed rounds.
Kanaph Therapeutics at a glance
Total raised
$73M
Latest round
Series C
Latest round date
January 2024
Headquarters
Seoul, South Korea
Notable investors
Lotte Biologics, GC Pharma, InterVest, Premier Partners, Solidus Investment, Daily Partners, NH Venture Investment, Aju IB Investment
Frequently asked about Kanaph Therapeutics funding
How much has Kanaph Therapeutics raised?
Kanaph Therapeutics has raised $73M in total disclosed funding across the rounds on record.
Who has invested in Kanaph Therapeutics?
Lotte Biologics, GC Pharma, InterVest, Premier Partners, Solidus Investment, Daily Partners are named among the investors backing Kanaph Therapeutics.
What was the latest Kanaph Therapeutics funding round?
The most recent disclosed round is a Series C, announced in January 2024.
Where is Kanaph Therapeutics based?
Kanaph Therapeutics is based in Seoul, South Korea.
When did Kanaph Therapeutics last raise?
The last disclosed Kanaph Therapeutics round closed in January 2024 at Series C.
Round data for Kanaph Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Seoul and backer lists below.
